Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
vaccine
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07574541CT.gov Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Triadeno Vaccine (this asset) | National Cancer Institute (NCI) | P2 | CCC · 52 |
| Cis-Diamminedichloroplatinum Ii | Mayo Clinic | P4 | BBB |
| Carboplatin | Blueprint Medicines Corporation | P4 | BBB |
| Irinotecan | University of Chicago | P2 | BBB |
| Cyclophosphamide | M.D. Anderson Cancer Center | P3 | BB |
| Icotinib | Betta Pharmaceuticals Co., Ltd. | P4 | BB |
| Desflurane | University of Zurich | P4 | BB |
| Fluorouracilum | University of Chicago | P2 | BB |
| Crizotinib | University of Birmingham | P2 | BB |
+42 more in the Adenocarcinoma cohort
Other indications for Triadeno Vaccine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Epithelial Neoplasm | — | P2 | CCC · 52 |
| Hepatocellular Carcinoma | — | P2 | CCC · 49 |
| Neoplasm | — | P2 | CC · 45 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Triadeno Vaccine in Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/triadeno-vaccine-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →